Jeraygo (Aprocitentan)

Aprocitentan blocks both ETA and ETB endothelin receptors on vascular smooth‑muscle cells, preventing endothelin‑1 induced vasoconstriction. This results in reduced peripheral vascular resistance and lower systemic arterial pressure.

The dose of Jeraygo is individualized and set by the prescribing healthcare professional based on the patient’s clinical condition, response to therapy, and any relevant laboratory parameters.

Safety of Aprocitentan in pregnancy and lactation has not been established. It is generally advised to avoid use in pregnant or nursing women unless the potential benefit justifies the potential risk.

To order Jeraygo, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Jeraygo belongs to the endothelin receptor antagonist class, which differs from conventional agents such as ACE inhibitors, ARBs, calcium‑channel blockers or diuretics. Its dual ETA/ETB blockade offers a distinct mechanism that can be effective when standard therapies fail, whereas other classes target the renin‑angiotensin system or calcium channels.

Jeraygo tablets should be stored at ambient temperature, preferably below 25 °C, in the original blister pack to protect from moisture and light. Keep the product out of reach of children and do not use after the expiry date.

Jeraygo is taken orally, usually with a glass of water. The tablet should be swallowed whole and not split, crushed or chewed unless otherwise directed by a healthcare professional.

Serious adverse events reported with Aprocitentan include significant hypotension, hepatic enzyme elevation, anemia, renal impairment, angioedema and pulmonary edema. Patients should be monitored regularly for these conditions, especially during treatment initiation and dose adjustments.

Jeraygo is contraindicated in patients with known hypersensitivity to Aprocitentan or any tablet excipients, in those with severe hepatic impairment, and in individuals where the risk of hypotension outweighs potential benefit. Caution is also advised for patients with pre‑existing renal disease.